STLN
The Oncology Institute, Inc.
6.40$
-2.3%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|
| -4.8% | -8.5% | -9.2% | 2.3% | -1.5% | 7.4% | 0.1% | |
| 1.7% | 1.5% | 1.3% | 1.1% | 1.1% | 1.1% | 1.2% | |
| 1.4% | 0.6% | 0.7% | 0.9% | 1.1% | 0.7% | 0.9% | |
| 3.0% | -2.7% | -4.5% | 5.4% | 0.6% | 8.9% | 2.8% | |
| 0.3% | 1.0% | 0.4% | 0.7% | 0.7% | 0.6% | 0.6% | |
| – | – | -0.4% | -0.7% | -0.7% | -0.6% | -0.6% | |
| -19.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| -4.5% | 1.6% | 7.8% | 2.6% | 0.0% | -0.1% | 2.4% | |
| -9.5% | -7.9% | -1.9% | 4.2% | -2.2% | 6.7% | 1.8% | |
| -5.1% | -9.5% | -9.7% | 1.5% | -2.2% | 6.8% | -0.6% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.